Evidence map›Paper›PMID 38892434›Full record

ArticleInternational journal of molecular sciences2024

Novel Lipid Nanocomplex Co-Carrying Bcl2 siRNA and Quantum Dots for EGF Receptor-Targeted Anti-Cancer Theranosis.

Moon Jung Choi, Seong Jae Kang, Yeon Kyung Lee, Kang Chan Choi, Do Hyun Lee, Hwa Yeon Jeong, Min Woo Kim, Keun Sik Kim, Yong Serk Park

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Moon Jung ChoiDepartment of Medicine, Brown University, Providence, RI 02903, USA.ORCID 0000-0003-4145-794X
Seong Jae KangDepartment of Biomedical Laboratory Science, Yonsei University, Wonju 26496, Republic of Korea.
Yeon Kyung LeeDepartment of Biomedical Laboratory Science, Yonsei University, Wonju 26496, Republic of Korea.
Kang Chan ChoiDepartment of Biomedical Laboratory Science, Yonsei University, Wonju 26496, Republic of Korea.ORCID 0009-0007-3937-2222
Do Hyun LeeDepartment of Biomedical Laboratory Science, Yonsei University, Wonju 26496, Republic of Korea.
Hwa Yeon JeongDepartment of Biomedical Laboratory Science, Yonsei University, Wonju 26496, Republic of Korea.
Min Woo KimDepartment of Biomedical Laboratory Science, Yonsei University, Wonju 26496, Republic of Korea.ORCID 0000-0002-5886-099X
Keun Sik KimDepartment of Biomedical Laboratory Science, Konyang University, Daejeon 35365, Republic of Korea.
Yong Serk ParkDepartment of Biomedical Laboratory Science, Yonsei University, Wonju 26496, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Many different types of nanoparticles have been suggested for tumor-targeted theranosis. However, most systems were prepared through a series of complicated processes and could not even overcome the blood-immune barriers. For the accurate diagnosis and effective treatment of cancers, herein we suggested the lipid micellar structure capturing quantum dot (QD) for cancer theranosis. The QD/lipid micelles (QDMs) were prepared using a simple self-assembly procedure and then conjugated with anti-epidermal growth factor receptor (EGFR) antibodies for tumor targeting. As a therapeutic agent, Bcl2 siRNA-cholesterol conjugates were loaded on the surface of QDMs. The EGFR-directed QDMs containing Bcl2 siRNA, so-called immuno-QDM/siBcl2 (iQDM/siBcl2), exhibited the more effective delivery of QDs and siBcl2 to target human colorectal cancer cells in cultures as well as in mouse xenografts. The effective in vivo targeting of iQDM/siBcl2 resulted in a more enhanced therapeutic efficacy of siBcl2 to the target cancer in mice. Based on the results, anti-EGFR QDM capturing therapeutic siRNA could be suggested as an alternative modality for tumor-targeted theranosis.

Indexed as

ErbB ReceptorsProto-Oncogene Proteins c-bcl-2Quantum DotsRNA, Small InterferingAnimalsCell Line, TumorHumansLipidsMiceMicellesNanoparticlesTheranostic NanomedicineXenograft Model Antitumor AssaysBCL2 protein, humanEGFR protein, humanErbB ReceptorsLipidsMicellesProto-Oncogene Proteins c-bcl-2RNA, Small Interferinglipid micellenanomedicinequantum dotsiRNA therapytheranosis

Identifiers

PMID38892434
PMCPMC11172456

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.